A Phase Ⅲ Study of JR-141 in Patients With Mucopolysaccharidosis II
Status:
Not yet recruiting
Trial end date:
2024-08-31
Target enrollment:
Participant gender:
Summary
A Global Phase III multicenter, randomized, assessor-blinded, active-controlled designed to
evaluate safety and efficacy of study drug for the treatment of the MPS II.